Pfizer said this Wednesday that the Food and Drug Administration of the United States (FDA, for its acronym in English) authorized its Covid-19 antiviral pill, making it the first home use treatment for coronavirus, which is expected to become an important tool in the fight against Omicron variant fast spreading.
Data from the clinical trial of Pfizer showed that their two-pill antiviral regimen was 90% effective in preventing hospitalizations and deaths in patients at high risk for severe disease. Recent laboratory data suggest that the drug maintains its efficacy against the Omicron variant.
The agency licensed the oral medication for treatment in high-risk adult patients and pediatric patients at least 12 years of age with Covid-19 outside the hospital.
The company said it was ready to start immediate supply in the United States and raised its production forecast to 120 million treatments from 80 million in 2022.
The US Government Contract for 10 Million Pfizer Drug Treatments is priced at $ 530 per treatment.
Pills Pfizer, which are taken together with the old antiviral ritonavir, will be sold under the brand Paxlovid. The pills should be taken every 12 hours for five days from the onset of symptoms.
Pfizer It has said it plans to submit a new drug application to the FDA in 2022 for possible full regulatory approval.
Reference-www.eleconomista.com.mx